Angle PLC Announces First Regional Distribution Agreement
ANGLE plc (OTCQX:ANPCY) has entered a distribution agreement with Promedeus to roll out the Parsortix system in the Czech Republic, targeting metastatic breast cancer. This partnership capitalizes on Promedeus's experience in advanced medical equipment distribution and oncology sector knowledge. The Parsortix system, which is FDA cleared and CE marked, enables non-invasive harvesting of circulating tumor cells from blood. ANGLE anticipates similar deals in other territories as it expands its market presence.
- Signed distribution agreement with Promedeus for Parsortix in the Czech Republic.
- Promedeus has expertise in oncological medical equipment and established customer relationships.
- Parsortix is FDA cleared and CE marked for use in metastatic breast cancer.
- None.
First regional distribution agreement for Parsortix
Specialist healthcare group Promedeus appointed to distribute the Parsortix system in the Czech Republic
GUILDFORD, UK / ACCESSWIRE / October 12, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce it has signed a distribution agreement with Promedeus s.r.o to enable and support the roll out of the FDA cleared and CE marked Parsortix® PC1 system across the Czech Republic for its intended use in metastatic breast cancer.
Promedeus, a part of the Vendeavour Group (a Private Equity fund with a focus on healthcare), has considerable expertise in distributing a range of advanced medical equipment into the Czech hospital and primary care markets with a track record for delivering high quality physician education and customer care.
With its extensive knowledge of the oncology sector in this region, Promedeus has already identified a number of clinical and research laboratory customers, including oncology centres of excellence, that it believes could be early adopters of the Parsortix platform.
Promedeus Founder, Viktor Ruzicka, commented:
"Promedeus is a distribution, sales and marketing company with clinical and laboratory branches. In oncology, the company combines radiotherapy, robotic and minimally invasive surgery including onco/neurosurgery with molecular biology, liquid biopsy, artificial intelligence image analysis, circulating tumor cell isolation and related disciplines and methods. We are looking forward to adding the ground-breaking Parsortix technology to our offering and bringing it successfully to the Czech market."
ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased to enter into this agreement with Promedeus and are encouraged by the efforts that the Promedeus team has already made to understand the benefits that the Parsortix system can bring to their oncology focused customer base. They have a strong track record and local knowledge which can help support the development of a new market for Parsortix. ANGLE expects to sign similar agreements for other key territories in due course."
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive | |
Berenberg (NOMAD and Joint Broker) | +44 (0) 20 3207 7800 |
|
|
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology known as the Parsortix® system and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's Parsortix® system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to harvest intact circulating cancer cells from blood.
Intended use
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
The Parsortix system enables a liquid biopsy (a simple blood test) to be used to provide the circulating metastatic breast cancer cells to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs harvested from the system enable a complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis as well as cytological and morphological examination and may provide comparable analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.
In the United States, the Parsortix® PC1 system has received a Class II Classification from FDA for use with metastatic breast cancer patients. FDA clearance is seen as the global gold standard. ANGLE's Parsortix system is the first ever FDA cleared system for harvesting CTCs for subsequent analysis. ANGLE has applied the IVD CE Mark to the same system for the same intended use in Europe.
ANGLE has also completed two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of
ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of
ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 70 peer-reviewed publications and numerous publicly available posters from 33 independent cancer centres, available on our website.
ANGLE has established clinical services laboratories in the UK and the United States to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services globally to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View source version on accesswire.com:
https://www.accesswire.com/720011/Angle-PLC-Announces-First-Regional-Distribution-Agreement
FAQ
What is the recent distribution agreement involving ANPCY?
What is the purpose of the Parsortix system by ANGLE plc?
When was the distribution agreement for Parsortix signed?
Who is Promedeus in relation to ANGLE plc?
What markets will ANGLE plc target beyond the Czech Republic?
